We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+12.33%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.81B
AUM Growth
+$59.5M
Cap. Flow
-$70.5M
Cap. Flow %
-3.88%
Top 10 Hldgs %
73.95%
Holding
42
New
–
Increased
9
Reduced
3
Closed
–

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$5.78M
2
EHTH icon
eHealth
EHTH
+$5.75M
3
BIIB icon
Biogen
BIIB
+$5.57M
4
ABMD
Abiomed Inc
ABMD
+$2.67M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$2.51M

Top Sells

Rank Stock Value
1
STAA icon
STAAR Surgical
STAA
+$71.9M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$24.1M
3
PRTA icon
Prothena Corp
PRTA
+$344K

Sector Composition

Rank Sector Weight
1 Healthcare 95.6%
2 Financials 3.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KLDO
26
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$5.85M 0.32%
786,400
– –
DNTH icon
27
Dianthus Therapeutics
DNTH
$6.29B
$4.23M 0.23%
27,019
– –
ZGNX
28
DELISTED
Zogenix, Inc.
ZGNX
$3.71M 0.2%
214,700
– –
KZR
29
DELISTED
Kezar Life Sciences
KZR
$3.56M 0.2%
65,620
– –
RIGL icon
30
Rigel Pharmaceuticals
RIGL
$782M
$2.83M 0.16%
65,240
– –
CYTK icon
31
Cytokinetics
CYTK
$10.5B
$2.45M 0.13%
123,686
– –
TVTX icon
32
Travere Therapeutics
TVTX
$5.86B
$2.42M 0.13%
166,069
– –
ALIM
33
DELISTED
Alimera Sciences
ALIM
$1.83M 0.1%
200,919
– –
ALDX icon
34
Aldeyra Therapeutics
ALDX
$91.7M
$1.82M 0.1%
160,800
– –
ATNX
35
DELISTED
Athenex, Inc. Common Stock
ATNX
$1.47M 0.08%
15,910
– –
TCMD icon
36
Tactile Systems Technology
TCMD
$555M
$1.41M 0.08%
27,100
– –
MRNS
37
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$562K 0.03%
31,330
– –
SYRS
38
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$439K 0.02%
8,060
– –
VIRX
39
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$377K 0.02%
33,212
– –
URGN icon
40
UroGen Pharma
URGN
$2.39B
$374K 0.02%
24,500
– –
ACGN
41
DELISTED
Aceragen Inc
ACGN
$92K 0.01%
4,537
– –
NERV icon
42
Minerva Neurosciences
NERV
$187M
$84K ﹤0.01%
4,540
– –
1
2

Similar funds

AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
PCM
Primavera Capital Management George Town, Cayman Islands $648M AUM 6.1% 1-Year Est. Return
HCM
Huber Capital Management El Segundo, California $647M AUM 24.91% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Palo Alto Investors's Q2 2021 Portfolio in Review

As of Q2 2021, Palo Alto Investors held 42 positions worth $1.81B, up 3.4% from $1.76B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Palo Alto Investors withdrew a net $70.5M in Q2 2021, reducing 3 holdings. Its largest reduction was STAAR Surgical, cutting an estimated $71.9M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Financials.

Against the trend, Palo Alto Investors added an estimated $5.78M to Insmed.

  • Palo Alto Investors added most to Insmed in Q2 2021, an estimated $5.78M increase.
  • Palo Alto Investors's biggest Q2 2021 reduction was STAAR Surgical, cutting an estimated $71.9M.
  • Palo Alto Investors's ten largest holdings make up 74% of its $1.81B portfolio in Q2 2021.
  • Palo Alto Investors opened 0 new positions and closed 0 in Q2 2021.
  • Palo Alto Investors's portfolio value rose 3.4% quarter-over-quarter to $1.81B.

Based on Palo Alto Investors's 13F filing for Q2 2021, filed 16 Aug 2021.